The Mechanism of Raf Activation Through Dimerization
Overview
Affiliations
Raf, a threonine/serine kinase in the Raf/MEK/ERK pathway, regulates cell proliferation. Raf's full activation requires dimerization. Aberrant activation through dimerization is an important therapeutic target. Despite its clinical importance, fundamental questions, such as how the side-to-side dimerization promotes the OFF-to-ON transition of Raf's kinase domain and how the fully activated ON-state kinase domain is stabilized in the dimer for Raf signaling, remain unanswered. Herein, we decipher an atomic-level mechanism of Raf activation through dimerization, clarifying this enigma. The mechanism reveals that the replacement of intramolecular π-π stacking by intermolecular π-π stacking at the dimer interface releases the structural constraint of the αC-helix, promoting the OFF-to-ON transition. During the transition, the inhibitory hydrophobic interactions were disrupted, making the phosphorylation sites in A-loop approach the HRD motif for -autophosphorylation. Once fully activated, the ON-state kinase domain can be stabilized by a newly identified functional N-terminal basic (NtB) motif in the dimer for Raf signaling. This work provides atomic level insight into critical steps in Raf activation and outlines a new venue for drug discovery against Raf dimerization.
Mechanism of dimer selectivity and binding cooperativity of BRAF inhibitors.
Clayton J, Romany A, Matenoglou E, Gavathiotis E, Poulikakos P, Shen J Elife. 2025; 13.
PMID: 39945510 PMC: 11825127. DOI: 10.7554/eLife.95334.
Impact of protein and small molecule interactions on kinase conformations.
Kugler V, Schwaighofer S, Feichtner A, Enzler F, Fleischmann J, Strich S Elife. 2024; 13.
PMID: 39088265 PMC: 11293870. DOI: 10.7554/eLife.94755.
Signaling pathways in colorectal cancer implications for the target therapies.
Song Y, Chen M, Wei Y, Ma X, Shi H Mol Biomed. 2024; 5(1):21.
PMID: 38844562 PMC: 11156834. DOI: 10.1186/s43556-024-00178-y.
Zhang W, Liu Y, Jang H, Nussinov R JACS Au. 2024; 4(5):1911-1927.
PMID: 38818077 PMC: 11134382. DOI: 10.1021/jacsau.4c00138.
Targeting RAF dimers in RAS mutant tumors: From biology to clinic.
Yin H, Tang Q, Xia H, Bi F Acta Pharm Sin B. 2024; 14(5):1895-1923.
PMID: 38799634 PMC: 11120325. DOI: 10.1016/j.apsb.2024.02.018.